UPDATE: Piper Jaffray Downgrades Arsanis Inc (ASNS) to Neutral Following Removal of ASN100 From Model

(Updated - June 28, 2018 10:25 AM EDT)

(updated to add analyst comment)

Piper Jaffray downgraded Arsanis Inc (NASDAQ: ASNS) from Overweight to Neutral with a price target of $7.00 (from $23.00).

Analyst Ed Tenthoff decides to await further info on ASN100 futility analysis and therefore steps to the sidelines.

The analyst also comments "Arsanis discontinued development of ASN100 after an independent data review committee unexpectedly deemed the ongoing Phase II study for prevention of Staph aureus pneumonia futile and unlikely to meet the primary endpoint. While too early to know the reason for failure, we believe every infection is different and a preventative approach with monoclonal antibodies holds promise for other infections. Antibodies have multi-fold mechanisms to neutralize and destroy microbes and long half-lives for durable effect."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Downgrades Disco Corp. (6146:JP) (DSCSY) to Neutral
• Phoenix Group (PHNX:LN) (PHXXF) PT Raised to GBP6.15 at RBC Capital
• Hays Plc. (HAS:LN) (HAYPF) PT Lowered to GBP1.30 at RBC Capital